Treatment of Ventilator-Associated Gram-Negative Pneumonia with Imipenem-Cilastatin/Amikacin Versus Ticarcillin-Clavulanate/Amikacin
Ventilator-associated pneumonia (VAP) is a common nosocomial infection in the intensive care unit (ICU). This study was performed in the Reanimation and Emergency ICUs of the Ankara D›flkap› Education and Research Hospital between January 1997 and January 2000. In a randomized, prospective trial, we...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bilimsel Tip Yayinevi
2006-06-01
|
| Series: | Flora Infeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi |
| Subjects: | |
| Online Access: | http://www.floradergisi.org/getFileContent.aspx?op=REDPDF&file_name=2006-11-2-096-101.pdf |
| Summary: | Ventilator-associated pneumonia (VAP) is a common nosocomial infection in the intensive care unit (ICU). This study was performed in the Reanimation and Emergency ICUs of the Ankara D›flkap› Education and Research Hospital between January 1997 and January 2000. In a randomized, prospective trial, we compared imipenem-cilastatin (500 mg four times a day) + amikacin (1 g single dose a day) with ticarcillin/clavulanate (3.1 g four times a day) + amikacin (1 g single dose a day) for the treatment of VAP in 35 adult ICU patients. In this study, there was no statistically significant difference between the mortality rates and risk factors of the group I patients and group II patients (p> 0.05). Our results demonstrate that in patients with VAP, there is no significant difference between combination therapy with ticarcillin-clavulanate/amikacin and imipenem-cilastatin/amikacin in terms of bacteriological eradication and clinical response. |
|---|---|
| ISSN: | 1300-932X 1300-932X |